You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology

    SBC: POINT DESIGNS, LLC            Topic: NICHD

    The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. TFEB Activator for Alzheimer's Disease Therapy

    SBC: BRILLIANT BIOSCIENCES INC.            Topic: NIA

    One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Technology Transfer of the ATLAS and ATHENA Programs

    SBC: Odyssey Science Innovations, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Technology for the non-invasive surveilance of post-traumatic compartment syndrome

    SBC: Myolex Inc            Topic: NIAMS

    PROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance

    SBC: Lyst Therapeutics LLC            Topic: NHLBI

    Project Description Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require surgical interventionComplications arising from the use of currently available prosthetic materials in the form of vascular graftspatchesor replaceme ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government